CN1264847C - 1-氧杂-3,9-二氮杂-螺[5.5]十一-2-酮衍生物及其作为神经激肽受体拮抗剂的用途 - Google Patents

1-氧杂-3,9-二氮杂-螺[5.5]十一-2-酮衍生物及其作为神经激肽受体拮抗剂的用途 Download PDF

Info

Publication number
CN1264847C
CN1264847C CNB028094735A CN02809473A CN1264847C CN 1264847 C CN1264847 C CN 1264847C CN B028094735 A CNB028094735 A CN B028094735A CN 02809473 A CN02809473 A CN 02809473A CN 1264847 C CN1264847 C CN 1264847C
Authority
CN
China
Prior art keywords
spiro
oxa
bis
trifluoromethyl
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB028094735A
Other languages
English (en)
Chinese (zh)
Other versions
CN1507449A (zh
Inventor
蔡海英
M·P·狄龙
G·加雷
A·格尔格勒
S·科茨威斯基
D·M·穆申斯基-鲍尔希
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of CN1507449A publication Critical patent/CN1507449A/zh
Application granted granted Critical
Publication of CN1264847C publication Critical patent/CN1264847C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10Spiro-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/537Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CNB028094735A 2001-05-14 2002-05-06 1-氧杂-3,9-二氮杂-螺[5.5]十一-2-酮衍生物及其作为神经激肽受体拮抗剂的用途 Expired - Fee Related CN1264847C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01111644 2001-05-14
EP01111644.9 2001-05-14

Publications (2)

Publication Number Publication Date
CN1507449A CN1507449A (zh) 2004-06-23
CN1264847C true CN1264847C (zh) 2006-07-19

Family

ID=8177412

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB028094735A Expired - Fee Related CN1264847C (zh) 2001-05-14 2002-05-06 1-氧杂-3,9-二氮杂-螺[5.5]十一-2-酮衍生物及其作为神经激肽受体拮抗剂的用途

Country Status (17)

Country Link
US (1) US6599900B2 (https=)
EP (1) EP1390372B1 (https=)
JP (1) JP4056887B2 (https=)
KR (1) KR100618063B1 (https=)
CN (1) CN1264847C (https=)
AR (1) AR033631A1 (https=)
AT (1) ATE401333T1 (https=)
AU (1) AU2002342238B2 (https=)
BR (1) BR0209604A (https=)
CA (1) CA2447329C (https=)
DE (1) DE60227657D1 (https=)
DK (1) DK1390372T3 (https=)
ES (1) ES2310206T3 (https=)
MX (1) MXPA03010321A (https=)
PT (1) PT1390372E (https=)
WO (1) WO2002092604A1 (https=)
ZA (1) ZA200308535B (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100863854B1 (ko) 2004-02-10 2008-10-15 에프. 호프만-라 로슈 아게 케모카인 ccr5 수용체 조절제
JP2008531509A (ja) 2005-02-25 2008-08-14 エフ.ホフマン−ラ ロシュ アーゲー 医薬品成分の改良された分散性を有する錠剤
KR101355064B1 (ko) * 2005-03-03 2014-01-24 얀센 파마슈티카 엔.브이. 치환된 옥사-디아자-스피로-[5.5]-운데카논 유도체 및뉴로키닌 길항제로서의 이의 용도
ATE478075T1 (de) 2005-03-08 2010-09-15 Janssen Pharmaceutica Nv Diazaspiro-ä4,4ü-nonanderivate als neurokinin- (nk1)-antagonisten
US7470684B2 (en) * 2007-01-03 2008-12-30 Hoffmann-La Roche Inc. Spiropiperidine derivatives as NK3 antagonists
WO2008090114A1 (en) 2007-01-24 2008-07-31 Glaxo Group Limited Pharmaceutical compositions comprising 2-methoxy-5- (5-trifluoromethyl-tetrazol-i-yl-benzyl) - (2s-phenyl-piperidin-3s-yl-)
JP2010522707A (ja) 2007-03-29 2010-07-08 エフ.ホフマン−ラ ロシュ アーゲー 抗ウイルス性複素環化合物
TN2017000544A1 (en) 2015-07-31 2019-04-12 Pfizer 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as magl inhibitors
RU2720203C1 (ru) 2017-01-20 2020-04-27 Пфайзер Инк. 1,1,1-трифтор-3-гидроксипропан-2-илкарбаматные производные как ингибиторы magl
CN110198944A (zh) 2017-01-23 2019-09-03 辉瑞大药厂 作为单酰基甘油脂肪酶抑制剂的杂环螺环化合物
WO2020048827A1 (en) 2018-09-03 2020-03-12 Bayer Aktiengesellschaft 1, 3, 9-triazaspiro[5.5] undecan-2-one compounds
WO2020048826A1 (en) 2018-09-03 2020-03-12 Bayer Aktiengesellschaft 5-substituted 1-oxa-3,9-diazaspiro[5.5]undecan-2-one compounds

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2131021B (en) * 1982-11-24 1985-12-18 Erba Farmitalia Antipsychotic benzoxazines
IL111960A (en) * 1993-12-17 1999-12-22 Merck & Co Inc Morpholines and thiomorpholines their preparation and pharmaceutical compositions containing them
DE69633245T2 (de) * 1995-09-29 2005-09-08 Eli Lilly And Co., Indianapolis Spiroverbindungen als Inhibitoren der Fibrinogen-abhängigen Blutplättchenaggregation

Also Published As

Publication number Publication date
CN1507449A (zh) 2004-06-23
CA2447329C (en) 2009-07-28
AU2002342238B2 (en) 2007-01-25
BR0209604A (pt) 2004-03-23
KR20030094405A (ko) 2003-12-11
MXPA03010321A (es) 2004-02-17
AR033631A1 (es) 2003-12-26
KR100618063B1 (ko) 2006-08-30
WO2002092604A1 (en) 2002-11-21
ZA200308535B (en) 2005-01-31
DK1390372T3 (da) 2008-09-15
JP2004534758A (ja) 2004-11-18
DE60227657D1 (de) 2008-08-28
EP1390372B1 (en) 2008-07-16
ES2310206T3 (es) 2009-01-01
EP1390372A1 (en) 2004-02-25
PT1390372E (pt) 2008-08-25
JP4056887B2 (ja) 2008-03-05
ATE401333T1 (de) 2008-08-15
US20030004163A1 (en) 2003-01-02
US6599900B2 (en) 2003-07-29
CA2447329A1 (en) 2002-11-21

Similar Documents

Publication Publication Date Title
CN1247588C (zh) 腺苷A2a受体拮抗剂
CN100351236C (zh) 用作5-羟色胺-6配体的1-杂环基烷基-3-磺酰基-吲哚衍生物,其制备方法和用途
CN1281605C (zh) 作为5-羟色胺-6配基的杂环基-吲唑或氮杂吲唑化合物
CN1092643C (zh) 用于增强记忆的氨甲基苯基咪唑衍生物
CN1231467C (zh) 伤害感受蛋白受体orl-1的高亲合性配体,包含它们的药物组合物以及它们的用途
CN1192032C (zh) 用作神经激肽-1受体拮抗剂的4-苯基-吡啶衍生物
CN1264847C (zh) 1-氧杂-3,9-二氮杂-螺[5.5]十一-2-酮衍生物及其作为神经激肽受体拮抗剂的用途
CN1150165C (zh) 用于治疗中枢神经系统紊乱的1-芳基磺酰基-2-芳基-吡咯烷衍生物
CN1602196A (zh) 作为腺苷调节剂的2-氨基苯并噻唑脲
CN1229373C (zh) 作为神经激肽1拮抗剂的哌啶衍生物
CN1202169A (zh) 作为5-ht4或h3受体配位体有效的5-苯基-3-(哌啶-4-基)-1,3,4-噁二唑-2(3h)-酮衍生物
CN1688581A (zh) [1,2,4]-三唑二环腺苷A2a受体拮抗剂
CN1492863A (zh) 作为5-羟色胺-6配基的杂环基烷基-吲哚或氮杂吲哚化合物
CN1468224A (zh) 用作α-2拮抗剂的喹啉衍生物
CN1946723A (zh) 取代的二氮杂-螺-[4.5]-癸烷衍生物及其作为神经激肽拮抗剂的应用
CN1198817C (zh) 作为组胺-h3激动剂或拮抗剂的n-(咪唑基烷基)取代的环胺
CN1756740A (zh) 具有2,6-二取代苯乙烯基的含氮杂环衍生物
CN1662544A (zh) 对血清素受体具有亲和力、可用作治疗剂的新型四环芳基磺酰吲哚、其制备方法及其药物组合物
CN1030753A (zh) 制备新的取代n-(3-羟基-4-哌啶基)苯甲酰胺的方法
CN1178923C (zh) 1,4-二氮杂环庚烷-2,5-二酮衍生物及其作为nk-1受体拮抗剂的应用
CN1274675C (zh) 环丁烯二酮化合物及其制备方法和含这些化合物的药物组合物
CN101035533A (zh) 抗精神分裂症的双重nk1/nk3拮抗剂
CN1272842A (zh) 作为速激肽受体拮抗剂的2-酰氨基丙胺类化合物
CN1249059C (zh) 新型哌啶羧酸酰胺衍生物、其制备方法以及含有它们的药物组合物
CN1875016A (zh) 咪唑衍生物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20060719

Termination date: 20110506